Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice
54
Citation
53
Reference
10
Related Paper
Citation Trend
Abstract:
Krabbe disease is an autosomal recessive disorder resulting from defects in the lysosomal enzyme galactocerebrosidase (GALC). GALC deficiency leads to severe neurological features. The only treatment for presymptomatic infantile patients and later-onset patients is hematopoietic stem cell transplantation (HSCT). This treatment is less than ideal with most patients eventually developing problems with gait and expressive language. Several naturally occurring animal models are available, including twitcher (twi) mice, which have been used for many treatment trials. Previous studies demonstrated that multiple injections of AAVrh10-GALC into the central nervous system (CNS) of neonatal twi mice resulted in significant improvements. Recently we showed that one i.v. injection of AAVrh10-GALC on PND10 resulted in normal GALC activity in the CNS and high activity in the peripheral nervous system (PNS). In the present study, a single i.v. injection of AAVrh10-GALC was given 1 day after bone marrow transplantation (BMT) on PND10. The mice show greatly extended lifespan and normal behavior with improved CNS and PNS findings. Since HSCT is the standard of care in human patients, adding this single i.v. injection of viral vector may greatly improve the treatment outcome. Krabbe disease is an autosomal recessive disorder resulting from defects in the lysosomal enzyme galactocerebrosidase (GALC). GALC deficiency leads to severe neurological features. The only treatment for presymptomatic infantile patients and later-onset patients is hematopoietic stem cell transplantation (HSCT). This treatment is less than ideal with most patients eventually developing problems with gait and expressive language. Several naturally occurring animal models are available, including twitcher (twi) mice, which have been used for many treatment trials. Previous studies demonstrated that multiple injections of AAVrh10-GALC into the central nervous system (CNS) of neonatal twi mice resulted in significant improvements. Recently we showed that one i.v. injection of AAVrh10-GALC on PND10 resulted in normal GALC activity in the CNS and high activity in the peripheral nervous system (PNS). In the present study, a single i.v. injection of AAVrh10-GALC was given 1 day after bone marrow transplantation (BMT) on PND10. The mice show greatly extended lifespan and normal behavior with improved CNS and PNS findings. Since HSCT is the standard of care in human patients, adding this single i.v. injection of viral vector may greatly improve the treatment outcome.Keywords:
Krabbe disease
Globoid cell leukodystrophy (GLD) or Krabbe disease is a neurodegenerative disorder caused by a deficiency of galactocerebrosidase (GALC) activity. GALC is required for the lysosomal degradation of galactosylceramide, psychosine, and possibly other galactolipids. This process is extremely important during active myelination. In the absence of functional GALC, psychosine accumulates, resulting in the apoptotic death of myelin-producing cells. While most patients are infants who do not survive beyond 2 years of age, some older patients are also diagnosed. Hematopoietic stem cell transplantation has proven to have a positive effect on the course of some patients with late-onset Krabbe disease. Murine models of this disease provide an excellent opportunity to evaluate therapeutic alternatives including gene therapy. In this study we used serotype 1 AAV to express mouse GALC under the control of the human cytomegalovirus promoter. Direct administration of these viral particles into the brains of neonatal mice with GLD resulted in sustained expression of GALC activity, improved myelination, attenuated symptoms, and prolonged life span. While this treatment also resulted in significant pathological improvements, the treated mice died with symptoms similar to those of the untreated mice. Additional initiatives may be required to prevent the onset of disease and reverse the course of the disease in animal models and human patients.
Krabbe disease
Lysosomal storage disease
Cite
Citations (97)
Krabbe disease or globoid cell leukodystrophy (GLD) is an autosomal recessive disorder of myelination caused by galactocerebrosidase (GALC) deficiency. This enzyme is essential for the lysosomal degradation of several important galactolipids, including galactosylceramide and psychosine. Most human patients present before 6 months of age but older patients are also recognized. The diagnosis can be made by measuring very low GALC activity in any easily obtainable tissue. Newborn screening has been initiated in an attempt to identify individuals who may develop the disease before symptoms appear. Treatment is limited to hematopoietic stem cell transplantation in presymptomatic infants and mildly affected late-onset patients. The GALC gene has been cloned, and over 140 disease-causing mutations have been identified. GLD has also been identified in a number of animal species, which can be used to examine pathogenic mechanisms and potential methods for treatment including gene therapy, stem cell therapy, and small molecule therapy.
Krabbe disease
Galactolipids
Lysosomal storage disease
Cite
Citations (4)
Krabbe disease
Galactolipids
Cite
Citations (29)
Krabbe disease
Pathogenesis
Cite
Citations (60)
Krabbe disease
Lysosomal storage disease
Heterozygote advantage
Cite
Citations (251)
Krabbe disease
Galactolipids
Cite
Citations (8)
Krabbe disease
Cite
Citations (38)
A case of Krabbe's leukodystrophy is reported in a male child 18 months old, with evolution of 12 months. The clinical, radiological, pathological and genetic studies are described. Besides, this case was the basis to review the topic of leukodystrophy and the corresponding literature, considering that this is an uncommon disease in our milieu.
Krabbe disease
Cite
Citations (0)